India, July 1 -- Shares of Can-Fite BioPharma Ltd. (CANF) climbed more than 36% on Wednesday morning after the company announced positive Phase 2a results for its pancreatic cancer candidate, Namodenoson.
The stock is currently trading at $4.06, up $1.09 or 36.73%, on the NYSE American. It opened at $5.02 after closing the previous session at $2.97. The stock has traded between $2.56 and $21.00 over the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Published by HT Digital Content Services with permission from RTT News....